Animal models and high field imaging and spectroscopy

Dialogues in Clinical Neuroscience

Volumn 15, Issue 3, 2013, Pages 263-278

  Öz, Gülin ^a   Tkáč, Ivan ^a   Uǧurbil, Kamil ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Brain function; Functional imaging; Neurometabolism; Spectroscopy

Indexed keywords

DOXYCYCLINE; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PHENCYCLIDINE; VIGABATRIN;

ALZHEIMER DISEASE; ARTICLE; BRAIN FUNCTION; DISEASE COURSE; EXPERIMENTAL MODEL; FUNCTIONAL MAGNETIC RESONANCE IMAGING; FUNCTIONAL NEUROIMAGING; HUMAN; MAGNETIC FIELD; MONITORING; NEUROCHEMISTRY; NEUROPATHOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROTON NUCLEAR MAGNETIC RESONANCE; RADIOLOGICAL PARAMETERS; SPECTROSCOPY;

BRAIN FUNCTION; FUNCTIONAL IMAGING; NEUROMETABOLISM; SPECTROSCOPY;

ANIMALS; BRAIN; BRAIN DISEASES; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, ANIMAL; SPECIES SPECIFICITY;

EID: 84888042111     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (160)

1. Ugurbil K, Adriany G, Andersen P, et al. Ultrahigh field magnetic resonance imaging and spectroscopy. Magn Reson Imaging. 2003;21:1263-1281.
2. Ugurbil K. The road to functional imaging and ultrahigh fields. Neuroimage. 2012;62:726-735.
3. Gruetter R, Weisdorf SA, Rajanayagan V, et al. Resolution improvements in in vivo 1H NMR spectra with increased magnetic field strength. J Magn Reson. 1998;135:260-264.
4. Lee SP, Silva AC, Ugurbil K, Kim SG. Diffusion-weighted spin-echo fMRI at 9.4 T: microvascular/tissue contribution to BOLD signal changes. Magn Reson Med. 1999;42:919-928.
5. Pfeuffer J, Tkac I, Choi IY, et al. Localized in vivo 1H NMR detection of neurotransmitter labeling in rat brain during infusion of [1-13C] D-glucose. Magn Reson Med. 1999;41:1077-1083.
6. Duong TQ, Kim DS, Ugurbil K, Kim SG. Spatiotemporal dynamics of the BOLD fMRI signals: toward mapping submillimeter cortical columns using the early negative response. Magn Reson Med. 2000;44:231-242.
7. Ugurbil K. Development of functional imaging in the human brain (fMRI); the University of Minnesota experience. Neuroimage. 2012;62:613-619.
8. Ogawa S, Tank DW, Menon R, et al. Intrinsic signal changes accompanying sensory stimulation: functional brain mapping with magnetic resonance imaging. Proc Natl Acad Sci U S A. 1992;89:5951-5955.
9. Kwong KK, Belliveau JW, Chesler DA, et al. Dynamic magnetic resonance imaging of human brain activity during primary sensory stimulation. Proc Natl Acad Sci U S A. 1992;89:5675-5679.
10. Bandettini PA, Wong EC, Hinks RS, Tikofsky RS, Hyde JS. Time course EPI of human brain function during task activation. Magn Reson Med. 1992;25:390-397.
11. Ogawa S, Menon RS, Tank DW, et al. Functional brain mapping by blood oxygenation level-dependent contrast magnetic resonance imaging. A comparison of signal characteristics with a biophysical model. Biophys J. 93;64:803-812.
12. Fujita N. Extravascular contribution of blood oxygenation level-dependent signal changes: a numerical analysis based on a vascular network model. Magn Reson Med. 2001;46:723-734.
13. Boxerman JL, Hamberg LM, Rosen BR, Weisskoff RM. MR contrast due to intravscular magnetic susceptiblity perturbations. Magn Reson Med. 1995;34:555-556.
14. Kennan RP, Zhong J, Gore JC. Intravascular susceptibility contrast mechanisms in tissue. Magn Reson Med. 1994;31:9-31.
15. Uludag K, Muller-Bierl B, Ugurbil K. An integrative model for neuronal activity-induced signal changes for gradient and spin echo functional imaging. Neuroimage. 2009;48:150-165.
16. Ugurbil K, Toth L, Kim DS. How accurate is magnetic resonance imaging of brain function? Trends Neurosci. 2003;26:108-114.
17. Ugurbil K, Adriany G, Andersen P, et al. Magnetic resonance studies of brain function and neurochemistry. Annu Rev Biomed Eng. 2000;2:633-660.
18. Kim SG, Ugurbil K. High-resolution functional magnetic resonance imaging of the animal brain. Methods. 2003;30:28-41.
19. Yacoub E, Duong TQ, Van De Moortele PF, et al. Spin-echo fMRI in humans using high spatial resolutions and high magnetic fields. Magn Reson Med. 2003;49:655-664.
20. Yacoub E, Van De Moortele PF, Shmuel A, Ugurbil K. Signal and noise characteristics of Hahn SE and GE BOLD fMRI at 7 T in humans. Neuroimage. 2005;24:738-750.
21. Vaughan JT, Garwood M, Collins CM, et al. 7T vs. 4T: RF power, homogeneity, and signal-to-noise comparison in head images. Magn Reson Med. 2001;46:24-30.
22. Duong TQ, Kim DS, Ugurbil K, Kim SG. Localized cerebral blood flow response at submillimeter columnar resolution. Proc Natl Acad Sci U S A. 2001;98:10904-10909.
23. Ugurbil K. Two decades of functional imaging: from nuclear spins to cortical columns. Cognitive Critique. 2012;4:121-186.
24. Ugurbil K. Imaging of brain function using deoxyhemoglobin and magnetic fields. In: Choi I-Y, Gruetter R, eds. Neural Metabolism In Vivo. New York, NY: Springer US.; 2012:501-545.
25. Engel SA, Glover GH, Wandell BA. Retinotopic organization in human visual cortex and the spatial precision of functional MRI. Cereb Cortex. 1997;7:181-192.
26. Ronen I, Olman C, Kim SG, Ugurbil K, Toth LJ. Spatial relationship between neuronal activity and BOLD functional MRI. Neuroimage. 2004;21:876-885.
27. Park JC, Ronen I, Kim D-S, Ugurbil K. Spatial specificity of high resolution GE BOLD and CBF fMRI in the cat visual cortex. Proc Intl Soc Mag Reson Med. 2004;12:1014.
28. Park JC, Ronen I, Kim D-S, Ugurbil K. Spatial specificity of high resolution GE BOLD and Spin Ech (SE) BOLD fMRI in the cat visual cortex at 9.4 Tesla. Proc Intl Soc Mag Reson Med. 2005;13:31.
29. Olman CA, Harel N, Feinberg DA, et al. Layer-specific fMRI reflects different neuronal computations at different depths in human V1. PLoS One. 2012;7:e32536.
30. Zimmermann J, Goebel R, De Martino F, et al. Mapping the organization of axis of motion selective features in human area MT using high-field fMRI. PLoS One. 2011;6:e28716.
31. Polimeni JR, Fischl B, Greve DN, Wald LL. Laminar analysis of 7T BOLD using an imposed spatial activation pattern in human V1. Neuroimage. 2010;52:1334-1346.
32. Koopmans PJ, Barth M, Orzada S, Norris DG. Multi-echo fMRI of the cortical laminae in humans at 7 T. Neuroimage. 2011;56:1276-1285.
33. Yacoub E, Shmuel A, Logothetis N, Ugurbil K. Robust detection of ocular dominance columns in humans using Hahn Spin Echo BOLD functional MRI at 7 Tesla. Neuroimage. 2007;37:1161-1177.
34. Yacoub E, Harel N, Ugurbil K. High-field fMRI unveils orientation columns in humans. Proc Natl Acad Sci U S A. 2008;105:10607-10612.
35. Menon RS, Ogawa S, Strupp JP, Ugurbil K. Ocular dominance in human V1 demonstrated by functional magnetic resonance imaging. J Neurophysiol. 1997;77:2780-2787.
36. Cheng K, Waggoner RA, Tanaka K. Human ocular dominance columns as revealed by high-field functional magnetic resonance imaging. Neuron. 2001;32:359-374.
37. Goodyear BG, Menon RS. Brief visual stimulation allows mapping of ocular dominance in visual cortex using fMRI. Hum Brain Mapp. 2001;14:210-217.
38. Fukuda M, Moon CH, Wang P, Kim SG. Mapping iso-orientation columns by contrast agent-enhanced functional magnetic resonance imaging: reproducibility, specificity, and evaluation by optical imaging of intrinsic signal. J Neurosci. 2006;26:11821-11832.
39. Sun P, Ueno K, Waggoner RA, Gardner JL, Tanaka K, Cheng K. A temporal frequency-dependent functional architecture in human V1 revealed by high-resolution fMRI. Nat Neurosci. 2007;10:1404-1406.
40. Zhao F, Wang P, Hendrich K, Ugurbil K, Kim SG. Cortical layer-dependent BOLD and CBV responses measured by spin-echo and gradient-echo fMRI: insights into hemodynamic regulation. Neuroimage. 2006;30:1149-1160.
41. Zhao F, Wang P, Kim SG. Cortical depth-dependent gradient-echo and spin-echo BOLD fMRI at 9.4T. Magn Reson Med. 2004;51:518-524.
42. Kim SG, Duong TQ. Mapping cortical columnar structures using fMRI. Physiol Behav. 2002;77:641-644.
43. Duong TQ, Silva AC, Lee SP, Kim SG. Functional MRI of calcium-dependent synaptic activity: cross correlation with CBF and BOLD measurements. Magn Reson Med. 2000;43:383-392.
44. Harel N, Lin J, Moeller S, Ugurbil K, Yacoub E. Combined imaging-histological study of cortical laminar specificity of fMRI signals. Neuroimage. 2006;29:879-887.
45. Goense JB, Logothetis NK. Laminar specificity in monkey V1 using highresolution SE-fMRI. Magn Reson Imaging. 2006;24:381-392.
46. Yu X, Glen D, Wang S, et al. Direct imaging of macrovascular and microvascular contributions to BOLD fMRI in layers IV-V of the rat whiskerbarrel cortex. Neuroimage. 2012;59:1451-1460.
47. Mandeville JB, Marota JJ, Kosofsky BE, et al. Dynamic functional imaging of relative cerebral blood volume during rat forepaw stimulation. Magn Reson Med. 1998;39:615-624.
48. Smirnakis SM, Schmid MC, Weber B, Tolias AS, Augath M, Logothetis NK. Spatial specificity of BOLD versus cerebral blood volume fMRI for mapping cortical organization. J Cereb Blood Flow Metab. 2007;27:1248-1261.
49. Leite FP, Tsao D, Vanduffel W, et al. Repeated fMRI using iron oxide contrast agent in awake, behaving macaques at 3 Tesla. Neuroimage. 2002;16:283-294.
50. Logothetis NK, Pauls J, Augath M, Trinath T, Oeltermann A. Neurophysiological investigation of the basis of the fMRI signal. Nature. 2001;412:150-157.
51. Logothetis NK. What we can do and what we cannot do with fMRI. Nature. 2008;453:869-878.
52. Kim DS, Ronen I, Olman C, Kim SG, Ugurbil K, Toth LJ. Spatial relationship between neuronal activity and BOLD functional MRI. Neuroimage. 2004;21:876-885.
53. Leopold DA, Maier A. Ongoing physiological processes in the cerebral cortex. Neuroimage. 2012;62:2190-2200.
54. Scholvinck ML, Maier A, Ye FQ, Duyn JH, Leopold DA. Neural basis of global resting-state fMRI activity. Proc Natl Acad Sci U S A. 1 2010;107:10238-10243.
55. Shmuel A, Leopold DA. Neuronal correlates of spontaneous fluctuations in fMRI signals in monkey visual cortex: Implications for functional connectivity at rest. Hum Brain Mapp. 08;29:751-761.
56. Liu X, Zhu XH, Zhang Y, Chen W. Neural origin of spontaneous hemodynamic fluctuations in rats under burst-suppression anesthesia condition. Cerebral Cortex. 2011;21:374-384.
57. Biswal B, Yetkin FZ, Haughton VM, Hyde JS. Functional connectivity in the motor cortex of resting human brain using echo-planar MRI. Magn Res Med. 1995;34:537-541.
58. Fox MD, Raichle ME. Spontaneous fluctuations in brain activity observed with functional magnetic resonance imaging. Nat Rev Neurosci. 2007;8:700-711.
59. Vincent JL, Patel GH, Fox MD, et al. Intrinsic functional architecture in the anaesthetized monkey brain. Nature. 2007;447:83-86.
60. Beckmann CF, DeLuca M, Devlin JT, Smith SM. Investigations into resting-state connectivity using independent component analysis. Philos Trans R Soc Lond B Biol Sci. 2005;360:1001-1013.
61. Smith SM, Miller KL, Salimi-Khorshidi G, et al. Network modelling methods for FMRI. Neuroimage. 2011;54:875-891.
62. Smith SM, Beckmann CF, Andersson J, et al. Resting-state fMRI in the Human Connectome Project. Neuroimage. 2013;80:144-168.
63. Kim S-G, Hu X, Ugurbil K. Accurate T1 determination from inversion recovery images: application to human brain at 4 Tesla. Magn Reson Med. 1994;31:445-449.
64. Jezzard P, Duewell S, Balaban RS. MR relaxation times in human brain: measurement at 4 T. Radiology. 1996;199:773-779.
65. Bartha R, Michaeli S, Merkle H, et al. In vivo HO T(dagger) measurement in the human occipital lobe at 4T and 7T by Carr-Purcell MRI: detection of microscopic susceptibility contrast. Magn Reson Med. 02;47:742-750.
66. Michaeli S, Garwood M, Zhu XH, et al. Proton T relaxation study of water, N-acetylaspartate, and creatine in human brain using Hahn and Carr-Purcell spin echoes at 4T and 7T. Magn Reson Med. 2002;47:629-633.
67. Norris DG. High field human imaging. J Magn Reson Imaging. 2003;18:519-529.
68. Rooney W, Johnson G, Li X, et al. Magnetic field and tissue dependencies of human brain longitudinal 1H2O relaxation in vivo. Magn Reson Med. 2007;57:308-318.
69. Dobre MC, Marjanska M, Ugurbil K. Blood T1 measurement at high magnetic field strength. Proc Intl Soc Mag Reson Med. 2005;13:1162.
70. Bolan PJ, Yacoub E, Garwood M, Ugurbil K, Harel N. In vivo micro-MRI of intracortical neurovasculature. NeuroImage. 2006;32:62-69.
71. Duyn JH, van Gelderen P, Li TQ, de Zwart JA, Koretsky AP, Fukunaga M. High-field MRI of brain cortical substructure based on signal phase. Proc Natl Acad Sci U S A. 2007;104:11796-11801.
72. Marques JP, Maddage R, Mlynarik V, Gruetter R. On the origin of the MR image phase contrast: an in vivo MR microscopy study of the rat brain at 14.1T. Neuroimage. 2009;46:345-352.
73. Sati P, van Gelderen P, Silva AC, et al. Micro-compartment specific T2* relaxation in the brain. Neuroimage. 2013;77:268-278.
74. Lee J, Shmueli K, Kang BT, et al. The contribution of myelin to magnetic susceptibility-weighted contrasts in high-field MRI of the brain. Neuroimage. 2012;59:3967-3975.
75. Fukunaga M, Li TQ, van Gelderen P, et al. Layer-specific variation of iron content in cerebral cortex as a source of MRI contrast. Proc Natl Acad Sci U S A. 2010;107:3834-3839.
76. Li TQ, Yao B, van Gelderen P, et al. Characterization of T* heterogeneity in human brain white matter. Magn Reson Med. 2009;62:1652-1657.
77. Lodygensky GA, Marques JP, Maddage R, et al. In vivo assessment of myelination by phase imaging at high magnetic field. Neuroimage. 2012;59:1979-1987.
78. Jack CR, Jr, Garwood M, Wengenack TM, et al. In vivo visualization of Alzheimer's amyloid plaques by magnetic resonance imaging in transgenic mice without a contrast agent. Magn Reson Med. 2004;52:1263-1271.
79. Jack CR, Jr., Wengenack TM, Reyes DA, et al. In vivo magnetic resonance microimaging of individual amyloid plaques in Alzheimer's transgenic mice. J Neurosci. 2005;25:10041-10048.
80. Jenkins BG, Kraft E. Magnetic resonance spectroscopy in toxic encephalopathy and neurodegeneration. Curr Opin Neurol. 1999;12:753-760.
81. Choi IY, Lee SP, Guilfoyle DN, Helpern JA. In vivo NMR studies of neurodegenerative diseases in transgenic and rodent models. Neurochem Res. 2003;28:987-1001.
82. Michaelis T, Boretius S, Frahm J. Localized proton MRS of animal brain in vivo: models of human disorders. Prog NMR Spect. 2009;55:1-34.
83. Duarte JM, Lei H, Mlynarik V, Gruetter R. The neurochemical profile quantified by in vivo 1H NMR spectroscopy. Neuroimage. 2012;61:342-362.
84. Dautry C, Vaufrey F, Brouillet E, et al. Early N-acetylaspartate depletion is a marker of neuronal dysfunction in rats and primates chronically treated with the mitochondrial toxin 3-nitropropionic acid. J Cereb Blood Flow Metab. 2000;20:789-799.
85. Jenkins BG, Klivenyi P, Kustermann E, et al. Nonlinear decrease over time in N-acetyl aspartate levels in the absence of neuronal loss and increases in glutamine and glucose in transgenic Huntington's disease mice. J Neurochem. 2000;74:2108-2119.
86. Bossuet C, Vaufrey F, Conde F, et al. Up-regulation of glutamate concentration in the putamen and in the prefrontal cortex of asymptomatic SIVmac251-infected macaques without major brain involvement. J Neurochem. 2004;88:928-938.
87. Dedeoglu A, Choi JK, Cormier K, Kowall NW, Jenkins BG. Magnetic resonance spectroscopic analysis of Alzheimer's disease mouse brain that express mutant human APP shows altered neurochemical profile. Brain Res. 2004;1012:60-65.
88. Emir UE, Auerbach EJ, Moortele PF, et al. Regional neurochemical profiles in the human brain measured by H MRS at 7 T using local B shimming. NMR Biomed. 2012;25:152-160.
89. Tkac I, Oz G, Adriany G, Ugurbil K, Gruetter R. In vivo 1H NMR spectroscopy of the human brain at high magnetic fields: metabolite quantification at 4T vs. 7T. Magn Reson Med. 2009;62:868-879.
90. Pfeuffer J, Tkac I, Provencher SW, Gruetter R. Toward an in vivo neurochemical profile: quantification of 18 metabolites in short-echo-time H NMR spectra of the rat brain. J Magn Reson. 1999;141:104-120.
91. Tkac I, Henry PG, Andersen P, Keene CD, Low WC, Gruetter R. Highly resolved in vivo 1H NMR spectroscopy of the mouse brain at 9.4 T. Magn Reson Med. 2004;52:478-484.
92. Schwarcz A, Natt O, Watanabe T, Boretius S, Frahm J, Michaelis T. Localized proton MRS of cerebral metabolite profiles in different mouse strains. Magn Reson Med. 2003;49:822-827.
93. Holmay MJ, Terpstra M, Coles LD, et al. N-acetylcysteine boosts brain and blood glutathione in gaucher and Parkinson diseases. Clin Neuropharmacol. 2013;36:103-106.
94. Tkac I, Oz G. In vivo proton MR spectroscopy: animal and human applications at high fields. In: Garrido L, Beckmann N, eds. New Applications of NMR in Drug Discovery and Development. London, UK: Royal Society of Chemistry.; 2013:237-258.
95. Bartha R, Drost DJ, Menon RS, Williamson PC. Comparison of the quantification precision of human short echo time H spectroscopy at 1.5 and 4.0 Tesla. Magn Reson Med. 2000;44:185-192.
96. Otazo R, Mueller B, Ugurbil K, Wald L, Posse S. Signal-to-noise ratio and spectral linewidth improvements between 1.5 and 7 Tesla in proton echoplanar spectroscopic imaging. Magn Reson Med. 2006;56:1200-1210.
97. Mekle R, Mlynarik V, Gambarota G, Hergt M, Krueger G, Gruetter R. MR spectroscopy of the human brain with enhanced signal intensity at ultrashort echo times on a clinical platform at 3T and 7T. Magn Reson Med. 2009;61:1279-1285.
98. Clark JB. N-acetyl aspartate: a marker for neuronal loss or mitochondrial dysfunction. Dev Neurosci. 1998;20:271-276.
99. Demougeot C, Garnier P, Mossiat C, et al. N-Acetylaspartate, a marker of both cellular dysfunction and neuronal loss: its relevance to studies of acute brain injury. J Neurochem. 2001;77:408-415.
100. Petroff OA, Pleban LA, Spencer DD. Symbiosis between in vivo and in vitro NMR spectroscopy: the creatine, N-acetylaspartate, glutamate, and GABA content of the epileptic human brain. Magn Reson Imaging. 1995;13:1197-1211.
101. Storm-Mathisen J, Danbolt NC, Rothe F, et al. Ultrastructural immunocytochemical observations on the localization, metabolism and transport of glutamate in normal and ischemic brain tissue. Prog Brain Res. 1992;94:225-241.
102. Oz G, Tkac I, Charnas LR, et al. Assessment of adrenoleukodystrophy lesions by high field MRS in non-sedated pediatric patients. Neurology. 2005;64:434-441.
103. Marjanska M, Curran GL, Wengenack TM, et al. Monitoring disease progression in transgenic mouse models of Alzheimer's disease with proton magnetic resonance spectroscopy. Proc Natl Acad Sci U S A. 2005;102:11906-11910.
104. Andreassen OA, Jenkins BG, Dedeoglu A, et al. Increases in cortical glutamate concentrations in transgenic amyotrophic lateral sclerosis mice are attenuated by creatine supplementation. J Neurochem. 2001;77:383-390.
105. Ottersen OP, Storm-Mathisen J. Glutamate-and GABA-containing neurons in the mouse and rat brain, as demonstrated with a new immunocytochemical technique. J Comp Neurol. 1984;229:374-392.
106. Palmi M, Brooke S, Smith AD, Bolam JP. GABA-like immunoreactivity in different cellular populations of cerebellar cortex of rats before and after treatment with amino-oxyacetic acid. Brain Res. 1991;543:277-286.
107. Brand A, Richter-Landsberg C, Leibfritz D. Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. Dev Neurosci. 1993;15:289-298.
108. Schuhmann MU, Stiller D, Skardelly M, et al. Metabolic changes in the vicinity of brain contusions: a proton magnetic resonance spectroscopy and histology study. J Neurotrauma. 2003;20:725-743.
109. Pouwels PJ, Kruse B, Korenke GC, Mao X, Hanefeld FA, Frahm J. Quantitative proton magnetic resonance spectroscopy of childhood adrenoleukodystrophy. Neuropediatrics. 1998;29:254-264.
110. Kantarci K, Petersen RC, Boeve BF, et al. 1H MR spectroscopy in common dementias. Neurology. 2004;63:1393-1398.
111. Vrenken H, Barkhof F, Uitdehaag BM, Castelijns JA, Polman CH, Pouwels PJ. MR spectroscopic evidence for glial increase but not for neuro-axonal damage in MS normal-appearing white matter. Magn Reson Med. 2005;53:256-266.
112. Fisher SK, Novak JE, Agranoff BW. Inositol and higher inositol phosphates in neural tissues: homeostasis, metabolism and functional significance. J Neurochem. 2002;82:736-754.
113. Kim JP, Lentz MR, Westmoreland SV, et al. Relationships between astrogliosis and 1H MR spectroscopic measures of brain choline/creatine and myo-inositol/creatine in a primate model. Am J Neuroradiol. 2005;26:752-759.
114. Urenjak J, Williams SR, Gadian DG, Noble M. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosci. 1993;13:981-989.
115. Bitsch A, Bruhn H, Vougioukas V, et al. Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton MR spectroscopy. Am J Neuroradiol. 1999;20:1619-1627.
116. Mountford CE, Stanwell P, Lin A, Ramadan S, Ross B. Neurospectroscopy: the past, present and future. Chem Rev. 2010;110:3060-3086.
117. Zacharoff L, Tkac I, Song Q, et al. Cortical metabolites as biomarkers in the R6/2 model of Huntington's disease. J Cereb Blood Flow Metab. 2012;32:502-514.
118. Tkac I, Henry PG, Zacharoff L, et al. Homeostatic adaptations in brain energy metabolism in mouse models of Huntington disease. J Cereb Blood Flow Metab. 2012;32:1977-1988.
119. Terpstra M, Marjanska M, Henry PG, Tkac I, Gruetter R. Detection of an antioxidant profile in the human brain in vivo via double editing with MEGA-PRESS. Magn Reson Med. 2006;56:1192-1199.
120. Tkac I, Rao R, Georgieff MK, Gruetter R. Developmental and regional changes in the neurochemical profile of the rat brain determined by in vivo 1H NMR spectroscopy. Magn Reson Med. 2003;50:24-32.
121. Valette J, Guillermier M, Besret L, Hantraye P, Bloch G, Lebon V. Isoflurane strongly affects the diffusion of intracellular metabolites, as shown by 1H nuclear magnetic resonance spectroscopy of the monkey brain. J Cereb Blood Flow Metab. 2007;27:588-596.
122. Lei H, Duarte JM, Mlynarik V, Python A, Gruetter R. Deep thiopental anesthesia alters steady-state glucose homeostasis but not the neurochemical profile of rat cortex. J Neurosci Res. 2010;88:413-419.
123. Baker M. In biomarkers we trust? Nat Biotechnol. 05;23:297-304.
124. Mlynarik V, Cacquevel M, Sun-Reimer L, et al. Proton and phosphorus magnetic resonance spectroscopy of a mouse model of Alzheimer's disease. J Alzheimers Dis. 2012;31(suppl 3):S87-S99.
125. Chassain C, Bielicki G, Keller C, Renou JP, Durif F. Metabolic changes detected in vivo by 1H MRS in the MPTP-intoxicated mouse. NMR Biomed. 10;23:547-553.
126. Emir UE, Tuite PJ, Oz G. Elevated pontine and putamenal GABA levels in mild-moderate Parkinson disease detected by 7 tesla proton MRS. PLoS One. 2012;7:e30918.
127. Heikkinen T, Lehtimaki K, Vartiainen N, et al. Characterization of neurophysiological and behavioral changes, MRI brain volumetry and 1H MRS in zQ175 knock-in mouse model of Huntington's disease. PLoS One. 2012;7:e50717.
128. Tkac I, Zacharoff L, Dubinsky JM. Longitudinal changes in neurochemical profiles of Huntington's disease mouse models. Paper presented at: 20th Scientific Meeting of the ISMRM; May 5-11, 2012; Melbourne, Australia.
129. Unschuld PG, Edden RA, Carass A, et al. Brain metabolite alterations and cognitive dysfunction in early Huntington's disease. Mov Disord. 2012;27:895-902.
130. van den Bogaard SJ, Dumas EM, Teeuwisse WM, et al. Exploratory 7-Tesla magnetic resonance spectroscopy in Huntington's disease provides in vivo evidence for impaired energy metabolism. J Neurol. 2011;258:2230-2259.
131. DeKosky ST, Marek K. Looking backward to move forward: early detection of neurodegenerative disorders. Science. 2003;302:830-834.
132. Burright EN, Clark HB, Servadio A, et al. SCA1 transgenic mice: a model for neurodegeneration caused by an expanded CAG trinucleotide repeat. Cell. 1995;82:937-948.
133. Oz G, Nelson CD, Koski DM, et al. Noninvasive detection of presymptomatic and progressive neurodegeneration in a mouse model of spinocerebellar ataxia type 1. J Neurosci. 2010;30:3831-3838.
134. Oz G, Hutter D, Tkac I, et al. Neurochemical alterations in spinocerebellar ataxia type 1 and their correlations with clinical status. Mov Disord. 2010;25:1253-1261.
135. Choi JK, Jenkins BG, Carreras I, et al. Anti-inflammatory treatment in AD mice protects against neuronal pathology. Exp Neurol. 2010;223:377-384.
136. Oz G, Vollmers ML, Nelson CD, et al. In vivo monitoring of recovery from neurodegeneration in conditional transgenic SCA1 mice. Exp Neurol. 2011;232:290-298.
137. Iltis I, Koski DM, Eberly LE, et al. Neurochemical changes in the rat prefrontal cortex following acute phencyclidine treatment: an in vivo localized H MRS study. NMR Biomed. 2009;22:737-744.
138. de Graaf RA, Patel AB, Rothman DL, Behar KL. Acute regulation of steady-state GABA levels following GABA-transaminase inhibition in rat cerebral cortex. Neurochem Int. 2006;48:508-514.
139. Petroff OA, Hyder F, Collins T, Mattson RH, Rothman DL. Acute effects of vigabatrin on brain GABA and homocarnosine in patients with complex partial seizures. Epilepsia. 1999;40:958-964.
140. Zhu XH, Merkle H, Kwag JH, Ugurbil K, Chen W. 17O relaxation time and NMR sensitivity of cerebral water and their field dependence. Magn Reson Med. 2001;45:543-549.
141. Hoult DI, Richards RE. The signal-to-noise ratio of the nuclear magnetic resonance phenomenon. J Magn Reson. 1976;24:71-85.
142. Zhu XH, Zhang Y, Tian RX, et al. Development of O NMR approach for fast imaging of cerebral metabolic rate of oxygen in rat brain at high field. Proc Natl Acad Sci U S A. 2002;99:13194-13199.
143. Zhang N, Zhu XH, Lei H, Ugurbil K, Chen W. Simplified methods for calculating cerebral metabolic rate of oxygen based on 17O magnetic resonance spectroscopic imaging measurement during a short 17O2 inhalation. J Cereb Blood Flow Metab. 2004;24:840-848.
144. Zhu XH, Zhang N, Zhang Y, Zhang X, Ugurbil K, Chen W. In vivo O NMR approaches for brain study at high field. NMR Biomed. 2005;18:83-103.
145. Zhu XH, Zhang N, Zhang Y, Ugurbil K, Chen W. New insights into central roles of cerebral oxygen metabolism in the resting and stimulus-evoked brain. J Cereb Blood Flow Metab. 2009;29:10-18.
146. Gruetter R, Seaquist ER, Ugurbil K. A mathematical model of compartmentalized neurotransmitter metabolism in the human brain. Am J Physiol Endocrinol Metab. 2001;281:E100-112.
147. Oz G, Berkich DA, Henry PG, et al. Neuroglial metabolism in the awake rat brain: CO2 fixation increases with brain activity. J Neurosci. 2004;24:11273-11279.
148. Choi IY, Gruetter R. In vivo 13C NMR assessment of brain glycogen concentration and turnover in the awake rat. Neurochem Int. 2003;43:317-322.
149. Choi IY, Seaquist ER, Gruetter R. Effect of hypoglycemia on brain glycogen metabolism in vivo. J Neurosci Res. 2003;72:25-32.
150. Gruetter R. Glycogen: the forgotten cerebral energy store. J Neurosci Res. 2003;74:179-183.
151. Gruetter R, Adriany G, Choi IY, Henry PG, Lei H, Oz G. Localized in vivo 13C NMR spectroscopy of the brain. NMR Biomed. 2003;16:313-338.
152. Oz G, Henry PG, Seaquist ER, Gruetter R. Direct, noninvasive measurement of brain glycogen metabolism in humans. Neurochem Int. 2003;43:323-329.
153. Seaquist ER, Damberg GS, Tkac I, Gruetter R. The effect of insulin on in vivo cerebral glucose concentrations and rates of glucose transport/metabolism in humans. Diabetes. 2001;50:2203-2209.
154. Choi IY, Lee SP, Kim SG, Gruetter R. In vivo measurements of brain glucose transport using the reversible Michaelis-Menten model and simultaneous measurements of cerebral blood flow changes during hypoglycemia. J Cereb Blood Flow Metab. 2001;21:653-663.
155. Chen W, Zhu XH, Gruetter R, Seaquist ER, Adriany G, Ugurbil K. Study of tricarboxylic acid cycle flux changes in human visual cortex during hemifield visual stimulation using H-{C} MRS and fMRI. Magn Reson Med. 2001;45:349-355.
156. Gruetter R, Ugurbil K, Seaquist ER. Steady-state cerebral glucose concentrations and transport in the human brain. J Neurochem. 1998;70:397-408.
157. Lei H, Ugurbil K, Chen W. Measurement of unidirectional Pi to ATP flux in human visual cortex at 7 T by using in vivo 31P magnetic resonance spectroscopy. Proc Natl Acad Sci U S A. 2003;100:14409-14414.
158. Oz G, Tesfaye N, Kumar A, Deelchand DK, Eberly LE, Seaquist ER. Brain glycogen content and metabolism in subjects with type 1 diabetes and hypoglycemia unawareness. J Cereb Blood Flow Metab. 2012;32:256-263.
159. Hattingen E, Magerkurth J, Pilatus U, et al. Phosphorus and proton magnetic resonance spectroscopy demonstrates mitochondrial dysfunction in early and advanced Parkinson's disease. Brain. 2009;132(Pt 12):3285-3297.
160. Oz G. MR Spectroscopy in health and disease. In: Manto M, Gruol DL, Schmahmann JD, Koibuchi N, Rossi F, eds. Handbook of the Cerebellum and Cerebellar Disorders. Vol 1. New York, NY: Springer Dordrecht.; 2013:713-733.